Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling

Cancer Research

Volumn 68, Issue 9, 2008, Pages 3350-3360

  Guo, Yi ^a   Xie, Jun ^a   Rubin, Elyssa ^a   Tang, Ya Xiong ^b   Lin, Fritz ^a   Zi, Xiaolin ^b   Hoang, Bang H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FRZB; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; WNT PROTEIN; FRZB PROTEIN; GELATINASE A; GLYCOPROTEIN; GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; ONCOPROTEIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG INHIBITION; FIBROSARCOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOFT TISSUE SARCOMA; TUMOR CELL; TUMOR GROWTH; XENOGRAFT; ANIMAL; CANCER INVASION; CELL ADHESION; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SECRETION; SIGNAL TRANSDUCTION; SOFT TISSUE TUMOR;

ANIMALS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FIBROSARCOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 44849108031     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-3220     Document Type: Article

References (46)

1. Clark MA, Fisher C, Judson I, et al. Soft tissue sarcomas in adults. N Engl J Med 2005;353:701-11.
2. Luu HH, Zhang R, Haydon RC, et al. Wnt/β-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 2004;4:653-71.
3. Zi X, Guo Y, Hoang BH, et al. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 2005;65:9762-70.
4. Dissanayake SK, Wade MS, Johnson CE, et al. The WNT5A/PKC pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors, and initiation of an epithelial to mesenchymal transition. J Biol Chem 2007;28:17259-71.
5. Tejpar S, Nollet F, Li C, et al. Predominance of β-catenin mutations and β-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18:6615-20.
6. Boon EM, Pouwels W, Redeker S, et al. Activation of Wnt signaling in the intestinal mucosa of Apc+/min mice does not cause overexpression of the receptor tyrosine kinase Met. Cancer Sci 2006;97:710-5.
7. Tomita H, Yamada Y, Oyama T, et al. Development of gastric tumors in Apc(Min/+) mice by the activation of the β-catenin/Tcf signaling pathway. Cancer Res 2007;67:4079-87.
8. Kim J, You L, Xu Z, et al. Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg 2007;133:733-7.
9. Mohinta S, Wu H, Chaurasia P, et al. Wnt pathway and breast cancer. Front Biosci 2007;12:4020-33.
10. Iwao K, Miyoshi Y, Nawa G, et al. Frequent β-catenin abnormalities in bone and soft tissue tumors. Jpn J Cancer Res 1999;90:205-9.
11. Saito T, Oda Y, Sakamoto A, et al. APC mutations in synovial sarcomas. J Pathol 2002;196:445-9.
12. Nagayama S, Fukukawa C, Katagiri T, et al. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene 2005;24:6201-12.
13. Mikami I, You L, He B, et al. Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. BMC Cancer 2005;5:53-9.
14. Hoang B, Moos M, Jr., Luyten FP, et al. Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J Biol Chem 1996;271:26131-7.
15. Wang S, Krinks M, Lin K, et al. FrzB, a secreted protein expressed in the Spermann organizer, binds and inhibits Wnt-8. Cell 1997;88:757-66.
16. Leyns L, Bouwmeester T, Kim SH, et al. Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell 1997;88:747-56.
17. Shanmugam KS, Brenner H, Hoffmeister M. et al. The functional genetic variant Arg324Gly of frizzled-related protein (FRZB) is associated with colorectal cancer risk. Carcinogenesis. Epub 2007 Apr 9.
18. Mandal D, Srivastava A, Mahlum E, et al. Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. Gene 2007;386:131-8.
19. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513-23.
20. Hoang BH, Kubo T, Gorlick R, et al. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway. Cancer Res 2004;64:2734-9.
21. Tsai CN, Tsai CL, Tse KP, et al. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A 2002;99:10084-9.
22. Ferracini R, Olivero M, Di Renzo MF, et al. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 1996;12:1697-705.
23. Patane S, Avnet S, Coltella N, et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 2006;66:4750-7.
24. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277-9.
25. Wu B, Crampton SP, Hughes CC. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 2007;26:227-39.
26. Marchenko GN, Marchenko ND, Leng J, Strongin AY. Promoter characterization of the novel human matrix metalloproteinase-26 gene: regulation by the T-cell factor-4 implies specific expression of the gene in cancer cells of epithelial origin. Biochem J 2002;363:253-62.
27. Bjornlan K, Flatmark K, Pettersen S, et al. Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res 2005;127:151-6.
28. Yuan J, Dutton CM, Scully SP. RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res 2005;23:1467-74.
29. Kawano Y, Kypta R. Secreted antagonists of the Wnt signaling pathway. J Cell Sci 2003;116:2627-34.
30. Ponzetto C, Giordano S, Peverali F, et al. c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 1991;6:553-9.
31. Fukuda T, Ichimura E, Shinozaki T, et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 1998;48:757-62.
32. Ferracini R, Di Renzo MF, Scotlandi K, et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995;10:739-49.
33. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility, and more. Nat Rev Mol Cell Biol 2003;4:915-25.
34. Van der Voort, Taher TE, Derksen PW, et al. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res 2000;79:39-90.
35. Taulli R, Scuoppo C, Bersani F, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006;66:4742-9.
36. Haydon RC, Deyrup A, Ishikawa A, et al. Cytoplasmic and/or nuclear accumulation of the β-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002;102:338-42.
37. Sievers S, Fritzsch C, Lehnhardt M, et al. Hypermethylation of the APC promoter but lack of APC mutations in myxoid/round-cell liposarcoma. Int J Cancer 2006;119:2347-52.
38. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:8319-26.
39. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548-58.
40. Guo Y, Zi X, Hoang BH, et al. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res 2007;25:964-71.
41. Vallin J, Thuret R, Giacomello E, et al. Cloning and characterization of three Xenopus Slug promoters reveal direct regulation by Lef/β-catenin signaling. J Biol Chem 2001;276:30350-8.
42. Howe LR, Watanabe O, Leonard J, Brown AM. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 2003;63:1906-13.
43. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
44. Taniwaki K, Fukamachi H, Komori, et al. Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res 2007;67:4311-9.
45. Entz-Werle N, Stoetzel C, Berard-Marec P, et al. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer 2005;117:349-55.
46. Dealmeida VI, Li M, Ernst JA, et al. The soluble Wnt receptor frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res 2007;67:5371-9.